Dr. Oh on Results of Chemotherapy Versus ARTA in Prostate Cancer | OncLive

Dr. Oh on Results of Chemotherapy Versus ARTA in Prostate Cancer

February 17, 2017

William Oh, MD, professor, Mount Sinai Hospital, discusses the results from a trial that compared second-line chemotherapy to alternative androgen receptor-targeted agents (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

William Oh, MD, professor, Mount Sinai Hospital, discusses the results from a trial that compared second-line chemotherapy to alternative androgen receptor-targeted agents (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

In this study, 345 patients who showed a lack of response to first-line ARTA were enrolled using Altos electronic medical records. Patients received either second-line docetaxel or cabazitaxel, or alternative ARTA.

Oh concludes that treatment with second-line chemotherapy proved more suitable for this patient subset than ARTA.

<<<

View more from the 2017 Genitourinary Cancers Symposium


x